Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026
Tokyo, Japan and Cambridge, UK, 1 May 2026 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31…
TME Pharma publishes its annual financial results and annual report
TME Pharma publishes its annual financial results and annual report Berlin, Germany, April 30, 2026, 20.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of…
Ex-Pharma Staff Booked For Fraudulent Government Tenders
Two former employees of a Delhi-based pharmaceutical firm have been booked for allegedly cheating and forging documents to fraudulently secure government tenders, including supplies to Army hospitals. Two former employees of a Delhi-based…
Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results
Press Release – No. 8 / 2026 Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results Copenhagen, Denmark and Boston, Massachusetts, April 30, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL)…
Swiss pharma firm Novartis plans seventh US plant
The new plant will be dedicated to the production of active pharmaceutical ingredients for solid formulations (tablets, capsules) as well as for RNA-based therapies, the Basel-based pharmaceutical group said in a press release on Thursday. The…
Curaleaf Completes Buyout of Remaining Stake in Germany's Four 20 Pharma
STAMFORD, Conn., April 30, 2026 /CNW/ -- Curaleaf Holdings, Inc (TSX: CURA) (OTCQX: CURLF) ('Curaleaf' or the 'Company'), a leading international provider of consumer products in cannabis, has completed the buyout of the remaining 45% stake not…
Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery Transcript
Hello. This is Paul Kuntz with RedChip Companies. I want to thank everyone for joining us for what promises to be an exciting session with Lantern Pharma. Today's session is centered around a live real-time demonstration of withZeta.ai, Lantern…
Eli Lilly: Stellar Q1 Earnings Put Pharma In Class Of Its Own, It's Ok To Buy Today (LLY)
Eli Lilly (LLY) delivered stellar Q1 2026 revenues of $19.8bn (+56% YoY) and EPS of $8.26 (+170% YoY), raising full-year guidance to $83.5bn at the midpoint. Lilly's growth is powered by the GLP-1 drugs Zepbound and Mounjaro, which now comprise 65%…
Broker's Call: Mankind Pharma (Buy)
Mankind Pharma's domestic formulation (DF) business is witnessing a healthy revival, with March 2026 growth at 11.5 per cent year on year vs. IPM growth at 10.6 per cent, driven by chronic therapies (cardiac up about 20 per cent/anti-diabetic up…
West Pharmaceutical: Multiple Growth Drivers Are A Tailwind (NYSE:WST)
West Pharmaceutical Services maintains dominant market share in injectable drug delivery, underpinned by a wide moat and robust regulatory positioning. WST reported strong Q1 2026 results, with revenue up 21% and adjusted EPS up 46.9%, prompting a…
Indian firms boost global acquisitions to $17.3 billion led by Sun Pharma deal
Sun Pharma's recent big-ticket acquisition of US-based Organon has put the spotlight on Indian companies increasingly making global acquisitions to gain market access and enhance capabilities. There have been more than 70 acquisitions of…
3 Boomerang-backed Pinnaql snaps up Pharma Resource Group
A verification email is on its way to you. Please check your spam or junk folder just in case. If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email:.
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares of Stock
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) CFO Terrance Coyne sold 34,791 shares of Royalty Pharma stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $49.78, for a total value of $1,731,895.98. The…
NewAmsterdam Pharma (NAMS) Expected to Announce Earnings on Thursday
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect NewAmsterdam Pharma to post earnings of ($0.46) per share and revenue of $1.0930 million…
Pictet Asset Management Holding SA Lowers Position in NewAmsterdam Pharma Company N.V. $NAMS
Pictet Asset Management Holding SA trimmed its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 42.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange…
Receive a Daily briefing on Pharma Industry News
Get Started